Clinical and economic burden of head and neck cancer: a nationwide retrospective cohort study from France

References

• GBD. 2015 Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global burden of disease study 2015. Lancet. 2016;388(10053):1545–1602. doi:10.1016/S0140-6736(16)31678-627733282
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Study 2015. Global Burden of Disease Study 2015 (GBD 2015) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2016 Available from: http://ghdx.healthdata.org/gbd-results-tool.
   Google Scholar
• Gatta G, Botta L, Sanchez MJ, et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2130–2143. doi:10.1016/j.ejca.2015.07.04326421817
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965. doi:10.1016/S1470-2045(16)30066-327247226
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. doi:10.1056/NEJMoa160225227718784
   PubMed Web of Science ®Google Scholar
• NICE. Nivolumab for treating squamous cell carcinoma of the head and neck after platinumbased chemotherapy; 2017 Available from: https://www.nice.org.uk/guidance/TA490/chapter/1-Recommendations. Accessed 1210, 2017.
   Google Scholar
• Ward MC, Shah C, Adelstein DJ, et al. Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer. Oral Oncol. 2017;74:49–55. doi:10.1016/j.oraloncology.2017.09.01729103751
   PubMed Web of Science ®Google Scholar
• Tringale KR, Carroll KT, Zakeri K, Sacco AG, Barnachea L, Murphy JD. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. J Natl Cancer Inst 2018;110(5):479–485. doi:10.1093/jnci/djx226.
   Google Scholar
• Wissinger E, Griebsch I, Lungershausen J, Foster T, Pashos CL. The economic burden of head and neck cancer: a systematic literature review. PharmacoEconomics. 2014;32(9):865–882. doi:10.1007/s40273-014-0169-324842794
   PubMed Web of Science ®Google Scholar
• Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(2):541–550.19190158
   PubMed Web of Science ®Google Scholar
• Jegu J, Binder-Foucard F, Borel C, Velten M. Trends over three decades of the risk of second primary cancer among patients with head and neck cancer. Oral Oncol. 2013;49(1):9–14. doi:10.1016/j.oraloncology.2012.06.01822840787
   PubMedGoogle Scholar
• Hollenbeak CS, Kulaylat AN, Mackley H, Koch W, Schaefer EW, Goldenberg D. Determinants of medicare costs for elderly patients with oral cavity and pharyngeal cancers. JAMA Otolaryngol Head Neck Surg. 2015;141(7):628–635. doi:10.1001/jamaoto.2015.094026042925
   PubMed Web of Science ®Google Scholar
• Gregoire V, Lefebvre JL, Licitra L, Felip E; Group E-E-EGW. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–186. doi:10.1093/annonc/mdq18520555077
   PubMed Web of Science ®Google Scholar
• Nijdam W, Levendag P, Noever I, Groot CU, Agthoven M. Cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications. Radiat Oncol. 2005;77(1):65–72. doi:10.1016/j.radonc.2005.09.007
   Web of Science ®Google Scholar
• Agence Technique de l’Information sur l’Hospitalisation (ATIH). Aide À L’utilisation Des Informations De Chaînage [How to Use De-Identified Patient Information]. Lyon, France: Agence Technique de l’Information sur l’Hospitalisation; 2014.
   Google Scholar
• Uhry Z, Belot A, Colonna M, et al. National cancer incidence is estimated using the incidence/mortality ratio in countries with local incidence data: is this estimation correct? Cancer Epidemiol. 2013;37(3):270–277. doi:10.1016/j.canep.2012.12.00723312453
   PubMedGoogle Scholar
• Schulman KL, Berenson K, Tina Shih YC, et al. A checklist for ascertaining study cohorts in oncology health services research using secondary data: report of the ISPOR oncology good outcomes research practices working group. Value Health. 2013;16(4):655–669. doi:10.1016/j.jval.2013.02.00623796301
   PubMedGoogle Scholar
• Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 8th ed New-York: Springer-Verlag; 2017.
   Google Scholar
• Barlow WE. Overview of methods to estimate the medical costs of cancer. Med Care. 2009;47(7 Suppl 1):S33–36. doi:10.1097/MLR.0b013e3181a2d84719536013
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.3558716
   PubMedGoogle Scholar
• Boje CR. Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma – a systematic review. Radiat Oncol. 2014;110(1):81–90. doi:10.1016/j.radonc.2013.07.005
   Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.16224307
   PubMed Web of Science ®Google Scholar
• Bannay A, Chaignot C, Blotiere PO, et al. The best use of the Charlson comorbidity index with electronic health care database to predict mortality. Med Care. 2016;54(2):188–194. doi:10.1097/MLR.000000000000047126683778
   PubMed Web of Science ®Google Scholar
• Institut National du Cancer (INCa). Algorithme De Sélection Des Hospitalisations Liées À La Prise En Charge Du Cancer Dans Les Bases Nationales D’activité Hospitalière De Court Séjour « Algorithme Cancer » [Algorithm to select cancer-related hospitalizations in the French National Hospital Discharge (PMSI) database] Boulogne-Billancourt: INCa; 2013.
   Google Scholar
• Distancier METRIC (MEsure des Trajets Inter-Communes/Carreaux)/Calculs « Licencié », licence n°201602996 [computer program]; 2014.
   Google Scholar
• Assurance Maladie. Rapport charges et produits pour l’année 2014. Assurance Maladie; 7 11, 2013.
   Google Scholar
• GBD. 2015 DALYs and HALE collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global burden of disease study 2015. Lancet. 2016;388(10053):1603–1658. doi:10.1016/S0140-6736(16)31460-X27733283
   PubMedGoogle Scholar
• Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling medicare expenditures. J Health Econ. 2004;23(3):525–542. doi:10.1016/j.jhealeco.2003.10.00515120469
   PubMed Web of Science ®Google Scholar
• Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461–494.11469231
   PubMed Web of Science ®Google Scholar
• GBD. 2015 Risk factors collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global burden of disease study 2015. Lancet. 2016;388(10053):1659–1724. doi:10.1016/S0140-6736(16)31679-827733284
   PubMed Web of Science ®Google Scholar
• Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol. 2014;50(5):387–403. doi:10.1016/j.oraloncology.2014.01.01624530208
   PubMed Web of Science ®Google Scholar
• Zigon G, Berrino F, Gatta G, et al. Prognoses for head and neck cancers in Europe diagnosed in 1995-1999: a population-based study. Ann Oncol. 2011;22(1):165–174. doi:10.1093/annonc/mdq30620587510
   PubMedGoogle Scholar
• Guizard AV, Uhry Z, de Raucourt D, et al. Trends in net survival from head and neck cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 2017;26:S16–S23. doi:10.1097/CEJ.000000000000029628005601
   PubMedGoogle Scholar
• St Guily JL, Borget I, Vainchtock A, Remy V, Takizawa C. Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database. Head Neck Oncol. 2010;2:22. doi:10.1186/1758-3284-2-2220809978
   PubMedGoogle Scholar
• Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102(2):82–88. doi:10.1093/jnci/djp47220056956
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797. doi:10.1056/NEJMp140515825162885
   PubMed Web of Science ®Google Scholar